IRIS UniCatt

Caldarola, Giacomo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.430
AS - Asia 4.911
EU - Europa 3.784
SA - Sud America 908
AF - Africa 149
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 6
Totale 15.205
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.266
SG - Singapore 2.339
DE - Germania 1.152
CN - Cina 1.093
BR - Brasile 754
VN - Vietnam 531
SE - Svezia 482
FR - Francia 443
IT - Italia 422
UA - Ucraina 251
FI - Finlandia 237
GB - Regno Unito 214
IE - Irlanda 165
IN - India 143
JP - Giappone 142
HK - Hong Kong 130
ID - Indonesia 125
RU - Federazione Russa 92
PL - Polonia 89
CA - Canada 78
AR - Argentina 63
IQ - Iraq 63
BD - Bangladesh 62
TR - Turchia 52
MX - Messico 48
KR - Corea 41
ES - Italia 38
NL - Olanda 37
ZA - Sudafrica 35
AT - Austria 34
EG - Egitto 33
SA - Arabia Saudita 32
BE - Belgio 27
EC - Ecuador 26
CI - Costa d'Avorio 23
PK - Pakistan 20
MA - Marocco 19
VE - Venezuela 16
CZ - Repubblica Ceca 14
JO - Giordania 14
KE - Kenya 14
LT - Lituania 14
AE - Emirati Arabi Uniti 13
MY - Malesia 13
PE - Perù 13
PH - Filippine 13
UZ - Uzbekistan 13
PT - Portogallo 12
RO - Romania 11
CO - Colombia 9
IR - Iran 9
KZ - Kazakistan 9
NZ - Nuova Zelanda 9
PY - Paraguay 9
AL - Albania 8
AU - Australia 8
TN - Tunisia 8
AZ - Azerbaigian 7
CL - Cile 7
HN - Honduras 7
PA - Panama 7
KG - Kirghizistan 6
NP - Nepal 6
BO - Bolivia 5
CH - Svizzera 5
CR - Costa Rica 5
HR - Croazia 5
IL - Israele 5
BG - Bulgaria 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
ET - Etiopia 4
EU - Europa 4
GR - Grecia 4
HU - Ungheria 4
NO - Norvegia 4
TW - Taiwan 4
UY - Uruguay 4
CY - Cipro 3
JM - Giamaica 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
LK - Sri Lanka 3
MD - Moldavia 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
BH - Bahrain 2
BN - Brunei Darussalam 2
GT - Guatemala 2
GY - Guiana 2
LU - Lussemburgo 2
PS - Palestinian Territory 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BB - Barbados 1
BY - Bielorussia 1
Totale 15.189
Salva come PNG Salva come JPEG
Città #
Singapore 1.215
Chandler 682
San Jose 573
Ashburn 569
Dallas 253
Beijing 204
Ho Chi Minh City 175
Dublin 160
New York 160
Lauterbourg 147
Jacksonville 146
Hefei 143
Los Angeles 135
San Mateo 133
Tokyo 128
Hanoi 127
Hong Kong 115
Helsinki 114
Jakarta 112
Frankfurt am Main 101
Munich 101
Nanjing 94
The Dalles 92
Milan 91
Rome 84
Wilmington 84
Ann Arbor 79
São Paulo 79
Boston 76
Houston 71
Woodbridge 67
Dearborn 63
Bremen 57
St Louis 54
Paris 53
Cattolica 48
Nürnberg 48
Moscow 46
Princeton 46
North Bergen 45
Boardman 44
Kent 42
Lawrence 42
Santa Clara 42
Kraków 41
Council Bluffs 37
London 37
Lappeenranta 36
Seoul 36
Da Nang 35
Chicago 33
Turku 33
Warsaw 33
Nanchang 32
Seattle 32
Redwood City 31
Rio de Janeiro 30
Marseille 29
Shanghai 28
Brooklyn 27
Nuremberg 27
Fairfield 26
Denver 25
Baghdad 24
Brussels 24
Abidjan 23
Düsseldorf 23
Montreal 23
Poplar 23
Curitiba 22
Atlanta 21
Orem 21
Haiphong 19
Leawood 19
Vienna 19
Amsterdam 18
Buffalo 18
Kunming 18
Stockholm 18
Brasília 17
Hebei 17
Hyderabad 17
Redmond 17
Toronto 17
Detroit 16
Jeddah 16
Johannesburg 16
Ankara 15
Tianjin 15
Chennai 14
Mexico City 14
Norwalk 14
Phoenix 14
Amman 13
Guangzhou 13
Shenyang 13
Belo Horizonte 12
Changsha 12
Izmir 12
Mumbai 12
Totale 8.187
Salva come PNG Salva come JPEG
Nome #
Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis. 245
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study 220
Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study. 207
Anti-TNF-α-induced psoriasiform lesions in IBD: an abnormal immune activation or a 'patchy cutaneous' immune suppression? 205
Linear atrophoderma of Moulin 196
Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis 185
Infliximab monotherapy in neuro-Behçet's disease: four year follow-up in a long-standing case resistant to conventional therapies 183
Psoriasis and polycystic ovary syndrome: a new link in different phenotypes 172
Usefulness of ultrasound imaging in detecting psoriatic arthritis of fingers and toes in patients with psoriasis. 167
Exacerbation of pemphigus after influenza vaccination. 167
Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data. 166
Circulating endothelial cell levels in psoriatic patients and their modification after an anti-TNF-alpha (Etanercept) treatment 164
Clinical and ultrasonographic profile of adalimumab-treated hidradenitis suppurativa patients: A real-life monocentric experience 163
A glass of red wine to keep vascular disease at bay, but what about pemphigus vulgaris? 162
Enteric-coated mycophenolate sodium as a steroid-sparing agent in pemphigus treatment: a retrospective study 159
Tumour necrosis factor-related apoptosis-inducing ligand (trail): a possible pathogenic role in chronic plaque psoriasis 157
HLA-Cw6 allele, NFkB1 and NFkBIA polymorphisms play no role in predicting response to etanercept in psoriatic patients 154
Management of recurrent cutaneous abscesses during therapy with infliximab 152
Infliximab monotherapy in neuro-Behçet's disease: four year follow-up in a long-standing case resistant to conventional therapies 148
Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study 147
Circumscribed pityriasis rubra pilaris type IV 146
IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses 143
Evaluation of Endothelial Dysfunction in Psoriatic Patients by Different Techniques 143
Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports 140
Lichenoid reaction induced by adalimumab 139
Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: A retrospective study 139
TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept 138
TNF-alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients 138
Bullous pemphigoid in a transplant recipient: is this a sign of allograft rejection? 136
Etanercept therapy for psoriasis in a patient with numerous comorbidities 132
development of pemphigus vulgaris in a patient with psoriasis treated with cyclosporine 130
TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept 130
Bullous pemphigoid in a transplant recipient: is this a sign of allograft rejection? 128
Psoriasis and erythema nodosum: two comorbidities of inflammatory bowel diseases 128
Psychopathology and eating disorders in patients with psoriasis 126
Dyshidrosiform pemphigoid: a well-defined clinical entity? 125
Drug survival of biologics and non-biologics in patients affected by palmoplantar psoriasis: a “real-world”, mono-center experience 123
Melanoma and non-melanoma skin cancer in psoriatic patients treated with high-dose phototherapy 123
Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients 122
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 121
Clinical, histopathological, and immunological evaluation of a series of patients with erythema nodosum 120
Human leukocyte antigen-B*58:01 allele in a familial case of Stevens-Johnson syndrome induced by allopurinol 119
Clinical, epidemiological, and therapeutic hallmarks of pyoderma gangrenosum: a case series of 35 patients 116
Clinico-dermoscopic features of alopecia areata in patients with psoriasis 116
Bullous pemphigoid in a transplant recipient: is this a sign of allograft rejection? 115
The preclinical discovery and development of deucravacitinib for the treatment of psoriasis 112
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 112
Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy 112
Ixekizumab exposure associated with myelitis: A case report and a literature review 112
Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice 111
Tumour necrosis factor-related apoptosis-inducing ligand (trail): a possible pathogenic role in chronic plaque psoriasis 110
Herpes simplex virus infection in pemphigus vulgaris: clinical and immunological considerations 109
Lichen sclerosus of the glans simulating melanoma 109
Biological agents targeting interleukin-13 for atopic dermatitis 109
New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flare-up after Sars-Cov-2 vaccination 108
Dermoscopy of cutaneous sarcoidosis. 107
Melanoma onset after estrogen, thyroid, and growth hormone replacement therapy. 106
A case of linear immunoglobulin A bullous dermatosis in a patient exposed to sun and an analgesic 105
Untreated Psoriasis Impairs Male Fertility: A Case-Control Study 105
Role of personalized medication training in improving efficacy and adherence to a topical therapy 105
Evaluation of Upadacitinib efficacy in the treatment of Atopic Dermatitis of sensitive areas 103
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study 102
Childhood trauma and resilience in psoriatic patients: A preliminary report. 102
New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis 102
Psoriasis and polycystic ovary syndrome: A new link in different phenotypes 101
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis) 100
Childhood trauma and resilience in psoriatic patients: A preliminary report 100
Successful treatment with tralokinumab in patients with atopic dermatitis and dupilumab-induced psoriasis 99
Dermoscopy of melanocytic lesions in patients affected by oculocutaneous albinism: a case series 97
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis) 94
Line-field confocal optical coherence tomography in alopecia areata and histopathological correlation 94
Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy 94
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry 93
2-Year Experience with Risankizumab in the Treatment of Plaque Psoriasis in Lazio Region, Italy 93
Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study 93
Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study 93
Eczematous eruption during bimekizumab treatment in a psoriatic patient previously treated with secukinumab 92
Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment 92
A possible role of polycystic ovary syndrome for pregnancy complications in women with psoriasis 91
Anti-IL-17 monoclonal antibodies and bullous pemphigoid: treatment or causal agents? A case series and review of the literature 90
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study 90
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study–IL PSO (Italian Landscape Psoriasis) 89
Living with chronic spontaneous urticaria in Italy: A narrative medicine project to improve the pathway of patient care 89
Anti-TNF-α-induced psoriasiform lesions in IBD: An abnormal immune activation or a 'patchy cutaneous' immune suppression? 89
Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: A 52-week Italian real-life experience 88
Psoriasis and erythema nodosum: two comorbidities of inflammatory bowel diseases 88
Evaluation of the Impact of Night Shift Work on Disease Severity in Psoriatic Patients: A Case-Control Study with Clinical, Hormonal, and Immunological Evaluation 87
Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region 86
Dermoscopy of necrobiosis lipoidica and granuloma annulare 85
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy 84
Linear IgA bullous dermatosis and ulcerative colitis treated by proctocolectomy 83
Granuloma faciale: a case report on long-term treatment with topical tacrolimus and dermoscopic aspects 83
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER–study) 83
Low grade of satisfaction related to the use of current systemic therapies among pustular psoriasis patients: a therapeutic unmet need to be fulfilled 82
Drug survival of methotrexate and predictor factors for discontinuation in psoriasis 82
A case of chronic disseminated lupus erythematosus in a psoriatic patient receiving ustekinumab 81
A case of eczematous eruption occurring during treatment with risankizumab 80
IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses 79
Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life. 79
Residual disease is the main, but not the only factor impacting satisfaction in psoriatic patients undergoing biological therapies 78
Totale 11.997
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.790
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.790
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021108 0 0 0 0 0 0 0 0 0 0 100 8
2021/2022671 75 55 20 19 35 21 10 113 17 40 129 137
2022/20231.787 219 255 118 281 145 222 64 139 238 22 60 24
2023/2024990 41 237 42 136 30 125 57 45 16 36 121 104
2024/20252.496 59 60 179 67 183 169 71 117 392 213 571 415
2025/20266.970 927 196 589 903 1.227 381 1.309 385 491 541 21 0
Totale 15.396